COVID-19: the use of immunotherapy in metastatic lung cancer

Immunotherapy. 2020 Jun;12(8):545-548. doi: 10.2217/imt-2020-0096. Epub 2020 Apr 30.

Authors

Alexander P Davis¹, Michael Boyer^{1

2}, Jenny H Lee^{1

3}, Steven C Kao^{1

2}

Affiliations

¹ Chris O'Brien Lifehouse, Department of Medical Oncology, 119-143 Missenden Road, Camperdown NSW 2050, Australia.
² Sydney Medical School, University of Sydney, NSW 2006, Australia.
³ Faculty of Medicine & Health, Macquarie University, NSW 2109, Australia.

No abstract available

Keywords: COVID-19; duration of therapy; immune checkpoint inhibitors; immunotherapy; lung cancer.

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use
COVID-19
Carcinoma, Non-Small-Cell Lung / complications*
Carcinoma, Non-Small-Cell Lung / mortality
Carcinoma, Non-Small-Cell Lung / secondary
Carcinoma, Non-Small-Cell Lung / therapy*
Coronavirus Infections / complications*
Coronavirus Infections / diagnosis
Coronavirus Infections / epidemiology
Coronavirus Infections / mortality
Humans
Immunotherapy / adverse effects*
Immunotherapy / mortality
Lung Neoplasms / complications*
Lung Neoplasms / mortality
Lung Neoplasms / secondary
Lung Neoplasms / therapy*
Pandemics
Pneumonia, Viral / complications*
Pneumonia, Viral / diagnosis
Pneumonia, Viral / epidemiology
Pneumonia, Viral / mortality
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / immunology
Programmed Cell Death 1 Receptor / therapeutic use
Risk Factors

Substances

Antibodies, Monoclonal, Humanized
PDCD1 protein, human
Programmed Cell Death 1 Receptor
atezolizumab